

FUSILLO, STRIZZI & ASSOCIATI

STUDIO LEGALE

Roma

Avv. Alessandro Fusillo
Patrocinante in Cassazione – Abogado (ICAM 120900)
Avv. Antonio Strizzi
Avv. Rocco Luigi Girolamo
Patrocinanti in Cassazione
Avv. Gabriele Guaitoli

OF COUNSEL

Schumann, Aldebert & Kollegen
Berlin- München

Attorneys for Freedom
Law Firm – Phoenix

..... and others v. Republic of Italy

List of documents

The original claim v. Italian Prime Minister and others

Folder 1

1. Claim (pages 1-61) with the POA (page 62) and index of the documents filed (pages 63-66)
2. Exhibits to the claim from 1 to 23 (pages 67-412):
 - 1) DETERMINA_154-2020_COMINRATY (pages 67-74)
 - 2) DETERMINA_18-2021_ASTRAZENECA (pages 75-82)
 - 3) DETERMINA_1-2021_MODERNA (pages 83-89)
 - 4) DETERMINA_49-2021_JANSEN (pages 90-96)
 - 5) Comirnaty European Medicines Agency (pages 97-106)
 - 6) Vaxzevria (previously COVID-19 Vaccine AstraZeneca) European Medicines Agency (pages 107-117)
 - 7) COVID-19 Vaccine Moderna European Medicines Agency (pages 118-127)
 - 8) COVID-19 Vaccine Janssen European Medicines Agency (pages 128-136)
 - 9) EMA_Comirnaty_dec_150522_it (pages 137-139)
 - 10) Cominarty-bugiardino-vaccino-pdf (pages 140-173)
 - 11) Vaxzevria-previously-covid-19-vaccine-astrazeneca-epar-product-information_it (pages 174-204)
 - 12) BugiardinoVaccinoAntiCovid-Moderna (pages 205-234)
 - 13) Covid-19-vaccine-janssen-epar-product-information_it (pages 235-269)
 - 14) Effetti avversi Pfizer Comirnaty (pages 270-296)

Roma

Viale delle Milizie, 22
00192 Roma
Tel. +39-06-3243832
Fax +39-06-87459135

Berlin

Katharinenstr. 18
10711 Berlin
Tel. +49-30-7577450
Fax +49-30-75774519

Madrid

Calle del Acuerdo, 17
28015 Madrid
Tel. +34-629-594770

Phoenix

3185 South Price Road
85248 Chandler (AZ) - USA
Tel. +1-480-7557110
Fax +1-480-8570150

- 15) Effetti avversi Vaxzevria (Atrazeneca) (pages 297-322)
- 16) Effetti avversi Moderna (pages 323-348)
- 17) Effetti avversi Janssen (pages 349-369)
- 18) In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine – PubMed (pages 370-371)
- 19) Chloroquine is a potent inhibitor of SARS coronavirus infection and spread (pages 372-385)
- 20) Antiviral Activity of Chloroquine against Human Coronavirus OC43 Infection in Newborn Mice (pages 386-397)
- 21) Stato e industria alleati per sconfiggere ogni coronavirus per sempre (pages 398-404)
- 22) Targeting SARS-CoV-2 viral proteases as a therapeutic strategy to treat COVID-19 – PubMed (pages 405-406)
- 23) Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro (pages 407-412)

Folder 2

3. Exhibits to the claim from 24 to 57 (pages 413-894)
 - 24) Breakthrough Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies (pages 413-490)
 - 25) Use of hydroxychloroquine in hospitalised COVID-19 patients is associated with reduced mortality Findings from the observational multicentre Italian CORIST study (pages 491-510)
 - 26) Vol_28_2_2020_9 (pages 511-516)
 - 27) Synergistic antiviral effect of hydroxychloroquine and azithromycin in combination against SARS-CoV-2 What molecular dynamics studies of virus-host interactions reveal (pages 517-533)
 - 28) COVID-19 outpatients early risk-stratified treatment with zinc plus low-dose hydroxychloroquine and azithromycin a retrospective case series study – ScienceDirect (pages 534-564)
 - 29) Hydroxychloroquine and azithromycin as a treatment of COVID-19 results of an open-label non-randomized clinical trial (pages 565-576)
 - 30) Coronavirus-abstract-spagnolo-2 (pages 577-579)
 - 31) Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy – PubMed (pages 580-582)

- 32) The versatile heparin in COVID-19 - Thachil - 2020 - Journal of Thrombosis and Haemostasis - Wiley Online Library (pages 583-589)
- 33) COME SI AFFRONTA IL COVID-19 (pages 590-609)
- 34) Potential therapeutic use of corticosteroids as SARS CoV-2 main protease inhibitors a computational study (pages 610-633)
- 35) Lactoferrin as potential preventative and adjunct treatment for COVID-19 – PubMed (pages 634-635)
- 36) Zinc and COVID-19 Basis of Current Clinical Trials (pages 636-651)
- 37) SARS-CoV-2 RNA reverse-transcribed and integrated into the human genome – PubMed (page 652)
- 38) Chloroquine is a zinc ionophore – PubMed (pages 653-654)
- 39) COVID-19 outpatients early risk-stratified treatment with zinc plus low-dose hydroxychloroquine and azithromycin a retrospective case series study – ScienceDirect (pages 655-684)
- 40) Nutrients Free Full-Text Effectiveness of In-Hospital Cholecalciferol Use on Clinical Outcomes in Comorbid COVID-19 Patients A Hypothesis-Generating Study HTML (pages 685-699)
- 41) Covid-19 trattamento Vitamina D (pages 700-701)
- 42) Vitamin D and Inflammation Potential Implications for Severity of Covid-19 – PubMed (page 702)
- 43) Nutrients Free Full-Text Vitamin D Supplementation Associated to Better Survival in Hospitalized Frail Elderly COVID-19 Patients The GERIA-COVID Quasi-Experimental Study HTML (pages 703-713)
- 44) Vitamin C and Immune Function (pages 714-745)
- 45) Vitamin C—An Adjunctive Therapy for Respiratory Infection, Sepsis and COVID-19 (pages 746-768)
- 46) The Emerging Role of Vitamin C in the Prevention and Treatment of COVID-19 (pages 769-779)
- 47) The clinical effects of vitamin C supplementation in elderly hospitalised patients with acute respiratory infections – PubMed (page 780)
- 48) 9781138337992_oachapter7 (pages 781-805)
- 49) Structural stability of SARS-CoV-2 3CLpro and identification of quercetin as an inhibitor by experimental screening – ScienceDirect (pages 806-808)

- 50) Flavonoids promising natural compounds against viral infections (pages 809-829)
- 51) Quercetin and Vitamin C An Experimental, Synergistic Therapy for the Prevention and Treatment of SARS-CoV-2 Related Disease (COVID-19) (pages 830-849)
- 52) A study on infectivity of asymptomatic SARS-CoV-2 carriers (pages 850-855)
- 53) COVID-19 i positivi asintomatici non sono contagiosi Torrinomedica (pages 856-857)
- 54) Scoglio, I tamponi Covid-19 producono fino al 95% di falsi positivi (pages 858-870)
- 55) VACCINAZIONE_ANTI-COVID19_MODULO_DI_CONSENSO (pages 871-880)
- 56) Circolare Ministero salute 25.03.2021_consens informato (pages 881-893)
- 57) Busta paga Gatti (page 894)

The further documents and briefs of the proceeding in the first instance before the Tribunal of Rome

Folder 3

- 4. Brief filed by the plaintiff's attorney (pages 895-919)
- 5. Index of the further documents submitted (page 920)
- 6. Exhibits 1-17 (pages 921-1183)
 - 1) Elenco professioni sanitarie (pages 921-922)
 - 2) Gazzetta ufficiale dell'Unione europea 17.05.2021 C189.o.A (pages 923-924)
 - 3) Gazzetta ufficiale dell'Unione europea C148 d.d. 26.04.2021- T136-21 - o.A (pages 925-926)
 - 4) Gazzetta ufficiale dell'Unione europea C148-21 d.d. 26.04.2021 - ricorso T96-21 o.A_ (pages 927-928)
 - 5) Nichtigkeitsklage Janssen Art. 263 AEUV_o.A_ (pages 929-983)
 - 6) Trad.It. T-96 21 azione annullamento UE Comirnaty Pfizer BioNTech (pages 984-1036)
 - 7) Parere Prof. S. Hockertz (pages 1037-1082)
 - 8) Morta 49enne vaccinata con AstraZeneca a Crotone, caso segnalato all'Aifa - Gazzetta del Sud (pages 1083-1084)
 - 9) Madre di tre figli muore dopo una terribile reazione ad AstraZeneca il dramma britannico.pdf (pages 1085-1087)
 - 10) Astrazeneca, gli atti "La verità sulla morte del militare" - Live Sicilia (pages 1088-1093)
 - 11) Malore fatale a 24 anni si era vaccinato il 5 giugno • Imola Oggi (pages 1094-1096)

- 12) Camilla morta a 18 anni. Fatale una trombosi dopo la dose AstraZeneca - Il Secolo XIX
(pages 1098-1107)
- 13) Bari, morto per trombosi a 54 anni dopo il vaccino J&J la famiglia sposterà denuncia
(pages 1108-1112)
- 14) Pfizer, morto ragazzo di 13 anni dopo il richiamo. «Era sano». Stati Uniti, aperta
inchiesta (pages 1113-1117)
- 15) CELEX 32021R0953 IT TXT (pages 1118-1139)
- 16) CELEX 32021R0953 EN TXT (pages 1140-1161)
- 17) CELEX 32021R0953 FR TXT (pages 1162-1183)

7. Index Intervention (pages 1184-1185)
8. Briefs of intervention, first to sixth (pages 1186-1316)
9. Powers of attorney for the Italian Court (samples) (pages 1317-1322)
10. Further explanatory brief by the interveners (pages 1323-1346)
11. Filing of the powers of attorney (sample) (pages 1347-1352)
12. Filing of the documents proving that the interveners are healthcare professionals (pages
1353-1357)

Folder 4

13. Defence brief of the defendants (pages 1358-1389) and attached document (pages 1390-
1398)
14. Further brief of the defendants (pages 1399-1413)
15. Writ of summons and protocol of the hearing (pages 1414-1415)

The decision in the first instance

16. Decision by the Tribunal in the first instance 19.07.2021 (pages 1416-1425)

The appeal procedure

17. Appeal (reclamo) (pages 1426-1535)
18. Exhibits with the appeal (1-8) (pages 1536-1596)
 - 1) Report_ISS_Istat_2021_10_giugno (pages 1536-1561)

- 2) Covid Italia, bollettino 31 dicembre_ contagi (24.477) e morti (555) in aumento, tasso di positività al 12,6% (pages 1562-1567)
- 3) Strategia dell'UE sui vaccini _ Commissione europea (pages 1568-1584)
- 4) Variante Delta, Fauci_ Stessa carica virale in vaccinati e non vaccinati (pages 1585-1586)
- 5) Fauci_ I vaccinati possono contrarre la variante Delta del Covid e contagiare. Gazzetta del Sud (pages 1587-1589)
- 6) Il 58% dei ricoverati in Israele per Covid-19 è vaccinato, così come 15 morti su 20 (dpnd) (pages 1590-1592)
- 7) Vaccinati e ricoverati in ospedale per Covid_ paradosso nel Regno Unito (eghq) (pages 1593-1594)
- 8) Pregliasco_ vaccinarsi vuol dire rischiare la propria vita (pages 1595-1596)

19. Writ of summons (page 1597)

20. Defence brief (pages 1598-1638) and attached document (pages 1639-1647)

21. Brief for the hearing (pages 1648-1663)

22. Documents attached to the brief (pages 1664-1683)

- 1) Nota AIFA sull'autorizzazione di cure (Anticorpi monoclonali) per la cura del Covid-19 (pages 1664-1666)
- 2) AIFA Determina 911/2021 (pages 1667-1679)
- 3) AIFA Determina 912/2021 (pages 1680-1683)

23. Hearing protocols (pages 1684-1685)

24. Request for filing of the decision (pages 1686-1687)

The final decision by the Tribunal of Rome

25. Final decision by the Tribunal of Rome 18.10.2021 (pages 1688-1784)

Supporting documents for the application to the ECHR

Folder 5

26. Gazzetta Ufficiale n. 79 1.04.2021 – pagg. 1-7 decreto-legge 44/2021 (pages 1785-1795)
27. Decreto-legge 1° aprile 2021 – versione in vigore al 9 marzo 2022 (pages 1796-1826)
28. Comirnaty, Annex 1, Summary of Product Characteristics (pages 1827-1937)
29. Spikevax, Annex I, Summary of Product Characteristics (pages 1938-1953)
30. Janssen, Annex I, Summary of Product Characteristics (pages 1954-1974)
31. Vaxzevria, Annex I, Summary of Product Characteristics (pages 1975-1988)
32. Nuvaxovid, Annex I, Summary of Product Characteristics (pages 1989-2001)
33. European Commission, Implementing decision 21.12.2020 Comirnaty (pages 2002-2005)
34. European Commission, Implementing decision 28.02.2022 Comirnaty (pages 2006-2008)
35. European Commission, Implementing decision 6.01.2021 Moderna (pages 2009-2012)
36. European Commission, Implementing decision 2.03.2022 Spikevax (Moderna) (pages 2013-2015)
37. European Commission, Implementing decision 11.03.2021 Janssen (pages 2016-2019)
38. European Commission, Implementing decision 2.03.2022 Janssen (pages 2020-2022)
39. European Commission, Implementing decision 29.01.2021 AstraZeneca (pages 2023-2026)
40. European Commission, Implementing decision 2.02.2022 Vaxzevria (AstraZeneca) (pages 2027-2029)
41. European Commission, Implementing decision 20.12.2021 Nuvaxovid (pages 2030-2033)
42. European Commission, Implementing decision 12.01.2022 Nuvaxovid (pages 2034-2036)
43. AIFA decision 154/2020 Comirnaty (pages 2037-2044)
44. AIFA decision 1/2021 Moderna (pages 2045-2052)
45. AIFA decision 18/2021 AstraZeneca (pages 2053-2060)
46. AIFA decision 49/2021 Janssen (pages 2061-2067)
47. AIFA decision 170/2021 Nuvaxovid (pages 2068-2074)
48. EMA overview Comirnaty (pages 2075-2079)
49. EMA overview Spikevax (pages 2080-2084)
50. EMA overview Janssen (pages 2085-2089)
51. EMA overview Vaxzevria (pages 2090-2094)
52. EMA overview Nuvaxovid (pages 2095-2098)
53. Comirnaty risk management plan (pages 2099-2187)

Folder 6

54. Moderna (Spikevax) risk management plan (pages 2188-2251)

FUSILLO, STRIZZI & ASSOCIATI
STUDIO LEGALE

55. PHMPT v. FDA Complaint with exhibits A1-A4 (pages 2252-2288)
56. US District Court for the Northern District of Texas – Order dated January 6th, 2022 (pages 2289-2292)
57. 5.3.6 Cumulative Analysis of Post-Authorization Adverse Events Reports (pages 2293-2330)
58. AIFA Annual report on the safety of the Covid-19 vaccines (27.12.2020-26.12.2021) (pages 2331-2385)
59. ISS (Istituto Superiore di Sanità) Characteristics of SARS-CoV-2 patients dying in Italy (10.01.2022) (pages 2386-2397)
60. Tweet Roberto Burioni July 23rd, 2021 (page 2398)
61. Draghi declarations July 22nd, 2021 (pages 2399-2400)
62. Sileri declarations January 26th, 2022 (pages 2401-2404)
63. The Lancet February 2022 Community transmission and viral load kinetics (pages 2405-2417)
64. The Lancet February 2022 What is the vaccine effect on reducing transmission in the context of the SARS-CoV-2 delta variant? (pages 2418-2419)
65. The Lancet April 2021 Covid-19 vaccine efficacy and effectiveness – the elephant (not) in the room (pages 2420-2421)
66. New England Journal of Medicine July 28th, 2021, Covid-19 Breakthrough Infections in Vaccinated Health Care Workers (pages 2422-2432)
67. The Atlantic September 16th, 2021, Stop Calling It a ‘Pandemic of the Unvaccinated’ (pages 2433-2437)
68. Morbidity and Mortality Weekly Report September 24th, 2021, Outbreak of SARS-CoV-2 B.1.617.2 (Delta) Variant Infections Among Incarcerated Persons in a Federal Prison – Texas, July-August 2021 (pages 2438-2443)
69. The Lancet January 2022 Transmissibility of SARS-CoV-2 among fully vaccinated individuals (page 2444)

Folders A-Z

- Powers of attorney by all other applicants